Polymorphism of BCL-2-like protein 11 (BIM) with different splicing variants resulted in lack of BH3 domain and resistance to targeted therapy in NSCLC positive for EGFR [125]. This evidence concerns the gene BCL2L11 and non-small cell lung carcinoma.